Our Work
Latham Advises Juvisé Pharmaceuticals in €550 Million Refinancing
February 17, 2026
Paris team represents the pharmaceutical company on the transaction.
Latham & Watkins has advised Juvisé Pharmaceuticals, a French pharmaceutical company, on a refinancing transaction with a total principal amount of €550 million, led by Hayfin Capital Management, a leading European alternative asset management platform.
The transaction includes €400 million of closing refinancing debt and a €150 million capital expenditure notes tranche to finance future M&A opportunities.
The Latham team was led by Paris partner Lionel Dechmann, with counsel Virginie Terzic and associates Bruna Neiva Cardante and Guillaume Bressand.